Bausch Health agrees to pay $1.21 billion to settle share price lawsuit

(Reuters) – Bausch Health Cos Inc (TO:) said on Monday it settled a class action lawsuit for $1.21 billion related to a drop in the drugmaker’s shares during 2013-2015.

The company, which was previously known as Valeant Pharmaceuticals (NYSE:), did not admit to any liability and denied all allegations of wrongdoing as part of the settlement for the litigation originally filed in October 2015.

The settlement, which is subject to court approval, does not impact the company’s current 2019 financial forecast, Bausch Health said.

The company’s U.S.-listed shares fell nearly 2% in trading before the bell.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.